Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I think it would be interesting to find job offers from Advent at Sawston UK.
That would be the confirmation of NWBO's positive data ...
I've searched through Linkedin, Monster, Google, unfortunately without any result!
Perhaps Advent prefers to remain anonymous and has entrusted the search for employees to specialized Agencies ...
.
New job
Quality Control Analyst I - Microbiology
https://www.linkedin.com/jobs/view/quality-control-analyst-i-microbiology-at-cognate-bioservices%2C-inc.-512323715?trkInfo=searchKeywordString%3ACognate%2BBioservices%2CsearchLocationString%3A%252C%2B%2Cvertical%3Ajobs%2CpageNum%3A1%2Cposition%3A9%2CMSRPsearchId%3A6ffbcc7a-7ba7-4ae2-a6c0-f09676edb194&refId=6ffbcc7a-7ba7-4ae2-a6c0-f09676edb194&trk=jobs_jserp_job_listing_text
Disappeared (strange): Environmental Health and Safety Specialist.
Published just on November 9
* Acts as administrative liaison for all environmental, occupational safety and health regulatory agency inspections and surveys, including FDA and OSHA. Communicates strategies, priorities, and recommends corrective actions to facility leadership, department managers, and employees.
* Experience interfacing with various regulatory agencies and auditors required.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=136104269
.
Last 15 hours, new job in Cognate Bioservices:
Environmental Health and Safety Specialist
* Acts as administrative liaison for all environmental, occupational safety and health regulatory agency inspections and surveys, including FDA and OSHA. Communicates strategies, priorities, and recommends corrective actions to facility leadership, department managers, and employees.
* Experience interfacing with various regulatory agencies and auditors required.
https://www.linkedin.com/jobs/view/environmental-health-and-safety-specialist-at-cognate-bioservices-485094048?trkInfo=searchKeywordString%3ACognate%2BBioservices%2CsearchLocationString%3A%252C%2BMemphis%252C%2BStati%2BUniti%2Cvertical%3Ajobs%2CpageNum%3A1%2Cposition%3A1%2CMSRPsearchId%3Ac5d1c8a9-03fe-430a-93de-3063d7ebd94a&refId=c5d1c8a9-03fe-430a-93de-3063d7ebd94a&trk=jobs_jserp_job_listing_text
.
- Could NWBO seek DCvax-Direct and DCvax-L contemporary approval?
- Maybe silence is due to DCvax-Direct results ... could the FDA approves DCvax-Direct with today's data, along with DCvax-L trial?
- (DCvax-Direct + DCvax-L) Accelerated Approval would be TSUNAMI news!
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
https://clinicaltrials.gov/ct2/show/NCT01882946?term=northwest+biotherapeutics&rank=2
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01882946
LOCATIONS:
- Orlando Health, Florida 32806
- MD Anderson Cancer Center, Houston 77030
.
Today new job in Cognate:
System Administrator II
https://www.linkedin.com/jobs/view/system-administrator-ii-at-cognate-bioservices%2C-inc.-502655313?trkInfo=searchKeywordString%3ACognate%2BBioservices%2CsearchLocationString%3AMemphis%252C%2BTN%2Cvertical%3Ajobs%2CpageNum%3A1%2Cposition%3A6%2CMSRPsearchId%3Abacda4ef-a457-470a-b46e-850f80ce2be0&refId=bacda4ef-a457-470a-b46e-850f80ce2be0&trk=jobs_jserp_job_listing_text
.
Flipper, as reported on your calendar and as indicated on the link below, NWBO should be present at the conference.
November 8-12 -- NWBO Exhibit (Booth) at Society for Immunotherapy of Cancer conference.
https://iplanprime.eventready.com/expomap/index.cfm?fuseaction=home.main&event_id=171
Unfortunately, I found on Yahoo the following post :
Do you think it's a fake news?
---------------------------------------------------------
Post on IHUB said NWBO - Linda Powers was going to present at SITC this November 9th, but I called today and they said that NWBO is not scheduled to even be at the conference.
The company is doing everything right by keeping total silence until WHAM!!!!! Just like Pearl Harbor to the shorts!!!!
Rumor is the publication that Bosch referred to has been authored by over 35 world class oncologists/surgeons, etc.
This has MAJOR written all over it!!!!!
https://finance.yahoo.com/quote/NWBO/community?p=NWBO
.
Partners in Progress: Cancer Patient Advocates and FDA Public Workshop.
https://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/OCE/ucm569922.htm?platform=hootsuite
.
I found on LINKEDIN, maybe there are different requests between Linkedin and Monster:
https://www.linkedin.com/jobs/search?keywords=cognate%20bioservices&location=Memphis%2C%20TN&locationId=PLACES.us.2-4-0-79-8&trk=jobs_jserp_search_button_execute&searchOrigin=JSERP&applyLogin=
.
Kats Cure
Kat lives in Milton Keynes in the UK... years ago she had GBM Brain Cancer...
https://www.docdroid.net/8Txspk9/kats-cure.doc#page=5
... March 17, 2016
... We are still waiting for the FDA to sign off their mid trial review of DCVAX, the wait is getting a bit agonizing and we are looking at what we can do. ...
... Sept 13, 2017
A few months back they thought a new site of tumor had grown. We left it a few months to scan and this week we went in for the results.
Again, this was a reaction to DCVAX doing it's work and have been told there is still no tumor and we getting close to 12 months clear!
This is obviously an amazing news and for us and will be celebrating!
DCVAX is working and we are getting our lives back!
We hope this brings as much of a smile To You as it does us. Xxx
-------------------------------------------------------
We do wish Kat all the best and really hope the vaccine keeps on working.
The company that produces DCVax-L is called Northwest Biotherapeutics and they are soon to release their Phase III trial results and if Kats story is anything to go by the FDA should hopefully be approving it for general use (even Standard Of Care)
Visit Kats facebook page https://www.facebook.com/katscure/
Also Kats fundraising page:
https://www.justgiving.com/fundraising/katscure
------------------------------------------------------
.
AVII77, thank you very, very much for your time spent searching the maps with the details shown in red.
I believe that NWBO will be able to purchase the remaining part of the property after FDA approval. Surely, the owners of the warehouses will ask for exaggerated prices. Maybe NWBO will prefer to build new buildings on its own land and deduct costs from taxes. Afterwards, NWBO will be able to buy the warehouses at reasonable prices ...
.
Thank you, my great disappointment ...
.
To AVII77
Thanks about photos/images but I did not undestood where are 514 acres that NWBO owns !!!
.
The boundaries of site near Sawston:
I would like to point on Google map the site of 514 acres near Sawston.
Unfortunately, I can't draw the borders over the map.
Anyway, in approximate way, I believe that site of 514 acres is delimited as follows:
- North: By city of Little Shelford to city of Great Shelford
- West: Whittlesford Rd
- East: Railway
- South: Near Whittlesford City
514 acres = 22,389,840 square feet = about 22 million square feet
Equivalent to a site of 10,000 feet x 2,200 feet
Or to a site of 4,700 feet x 4,700 feet
https://www.google.it/maps/@52.1354189,0.1396058,3625m/data=!3m1!1e3
.
To Happy L. and Virgilio:
The POST from Yahoo is NOT mine ...
I would like to convey to the attention of the HiHub board the phrases highlighted in red !!!
, not concerned as i was with the trial design. FDA has shown a high level of approval for new immogrphy treatments as recent as 2 days ago.
Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases.
In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer,” said FDA Commissioner Scott Gottlieb, M.D. “This approval demonstrates the continued momentum of this promising new area of medicine and we’re committed to supporting and helping expedite the development of these products. We will soon release a comprehensive policy to address how we plan to support the development of cell-based regenerative medicine. That policy will also clarify how we will apply our expedited programs to breakthrough products that use CAR-T cells and other gene therapies. We remain committed to supporting the efficient development of safe and effective treatments that leverage these new scientific platforms.”
The approval of Yescarta brings this innovative class of CAR-T cell therapies to an additional group of cancer patients with few other options – those adults with certain types of lymphoma that have not responded to previous treatments,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER).
The safety and efficacy of Yescarta were established in a multicenter clinical trial of more than 100 adults with refractory or relapsed large B-cell lymphoma. The complete remission rate after treatment with Yescarta was 51 percent.Each dose of Yescarta is a customized treatment created using a patient’s own immune system to help fight the lymphoma. The patient’s T-cells, a type of white blood cell, are collected and genetically modified to include a new gene that targets and kills the lymphoma cells. Once the cells are modified, they are infused back into the patient.
Now if this trial was going south do you really think Linda Liau and UCLA would have received 11M grant. IMO this delay is due to NWBO making certain they have prepared the data for a flawless presentation. There is no way that this silence continues much longer as management's biggest challenge and fear is a leak before the release
https://finance.yahoo.com/quote/NWBO/community?p=NWBO
.
Below an Interesting Post from Yahoo:
, not concerned as i was with the trial design. FDA has shown a high level of approval for new immogrphy treatments as recent as 2 days ago.
Today marks another milestone in the development of a whole new scientific paradigm for the treatment of serious diseases. In just several decades, gene therapy has gone from being a promising concept to a practical solution to deadly and largely untreatable forms of cancer,” said FDA Commissioner Scott Gottlieb, M.D. “This approval demonstrates the continued momentum of this promising new area of medicine and we’re committed to supporting and helping expedite the development of these products. We will soon release a comprehensive policy to address how we plan to support the development of cell-based regenerative medicine. That policy will also clarify how we will apply our expedited programs to breakthrough products that use CAR-T cells and other gene therapies. We remain committed to supporting the efficient development of safe and effective treatments that leverage these new scientific platforms.” The approval of Yescarta brings this innovative class of CAR-T cell therapies to an additional group of cancer patients with few other options – those adults with certain types of lymphoma that have not responded to previous treatments,” said Peter Marks, M.D., Ph.D., director of the FDA’s Center for Biologics Evaluation and Research (CBER).
The safety and efficacy of Yescarta were established in a multicenter clinical trial of more than 100 adults with refractory or relapsed large B-cell lymphoma. The complete remission rate after treatment with Yescarta was 51 percent.Each dose of Yescarta is a customized treatment created using a patient’s own immune system to help fight the lymphoma. The patient’s T-cells, a type of white blood cell, are collected and genetically modified to include a new gene that targets and kills the lymphoma cells. Once the cells are modified, they are infused back into the patient.
Now if this trial was going south do you really think Linda Liau and UCLA would have received 11M grant. IMO this delay is due to NWBO making certain they have prepared the data for a flawless presentation. There is no way that this silence continues much longer as management's biggest challenge and fear is a leak before the release
https://finance.yahoo.com/quote/NWBO/community?p=NWBO
.
The design also included 4 rentable ‘hotel’ suites for start-up projects…
Scheme: Genetic and Cellular Therapy Laboratories
Client: Undisclosed
Value: £18m
Description:
AHP were appointed as lead designer for the refurbishment of an existing distribution depot and associated offices. The refurbishment provided the client with state of the art genetic and cellular therapy, GMP manufacturing facilities in class D, C and B cleanroom laboratories with associated accommodation, including temperature-controlled quarantine storage, microbiology testing laboratories, process development laboratories, cryogenic shipping, secure data storage, administration offices, staff recreation and changing areas.
The design also included 4 rentable ‘hotel’ suites for start-up projects. Each self-contained unit includes laboratory and EM microbiology facilities, and administration space.
https://www.ahpltd.co.uk/genetherapy (photos and description)
https://www.ahpltd.co.uk/biotechnology (other designed laboratories)
* Below as text appeared long ago:
AHP are pleased to have been instructed by a leading Bio Science company in the development of a new commercial validated GMP compliant manufacturing facility and state of the art Research and Development Laboratories in South Cambridge. Our client has extensive experience in the development of cell-based therapeutics in the USA and are now developing the first commercial scale manufacturing facility in England.
The South Cambridge Site offers the opportunity for further expansion and the vision is for the development of a healthcare campus providing both manufacturing and patient treatment in the same locality.
.
... director's tasks have so far been fulfilled by Linda Fairing Powers who was ...
Aracaris Capital Limited (NWBO subsidiary in the UK that owns the property in Sawston):
Description
Data updated on: 01-10-2017
Aracaris Capital Limited may be reached at 20-22 Bedford Row, in London. The company's postal code is WC1R 4JS. Aracaris Capital has been operating on the British market for the last 3 years. The company's Companies House Registration Number is 09103328. This enterprise's SIC code is 68209 which means Other letting and operating of own or leased real estate. The business latest accounts cover the period up to 2015/12/31 and the most current annual confirmation statement was submitted on 2017/06/26.
As for the following limited company, the full range of director's tasks have so far been fulfilled by Linda Fairing Powers who was appointed in 2014. Since 2014-06-26 Jason Antony Reader, age 45 from London had been fulfilling assigned duties for this specific limited company till the resignation 2 years ago. In addition another director, specifically Martin William Gordon Palmer, age 58 from London quit 2 years ago. At least one secretary in this firm is a limited company: Jordan Cosec Limited.
Financial data based on annual reports: …
http://www.bizdb.co.uk/company/aracaris-capital-limited-09103328/
… and more:
Company Officers of ARACARIS CAPITAL LIMITED
http://www.datalog.co.uk/browse/detail.php/CompanyNumber/09103328/CompanyName/ARACARIS+CAPITAL+LIMITED
Secretary's details changed for Jordan Cosec Limited on 16th August 2017
http://www.bizdb.co.uk/company/aracaris-limited-09103355/
.
Jack, could you please clarify what you mean on the point 1 and 2:
1) … the building housing Northwest Bio is fully refurbished …
… and the Northwest Bio area approx 5 acres has a commercial land price of around £1m per acre …
(Who is owns, Northwest or Cognate?)
2) … The site they own is 514 acres in total …
(That is immense area, it equals about 200 baseball fields)
Acres baseball field: National League parks tend to be bigger with six of the seven biggest and an average of 2.51 acres. American League parks have an average of 2.46 acres.
Therefore 514 acres : average 2.46 = 209 baseball fields …
Northwest-Cognate, maybe they have in mind to make a Great Biopharma Polo?
Or, they will sell plots of land at tenfold price?
.
Expanded Access: FDA Describes Efforts to Ease Application Process
Posted on October 3, 2017 by FDA Voice
By: Scott Gottlieb, M.D.
https://blogs.fda.gov/fdavoice/index.php/2017/10/expanded-access-fda-describes-efforts-to-ease-application-process/
.
Learn more about how the market maker NITE affects the penny stock market.
What should you do when you see NITE on the bid or ask?
http://www.penny-stock-brokers.org/mm-nite-shorting/
Market Maker NITE playing his Fraudulent Games:
The website sometimes appears completely white and sometimes with 6 points, as it is indicated below.
From each point you access new pages with five new points that lead to strange links (I believe test links)...
- Cancer Research
- Biotechnology Company
- Cancer Vaccines
- Metastatic Melanoma
- Therapeutic Treatment
- Pharmaceutical Company
- Drug Development
I bought AVAX shares in 2010, then a slow decline in value per share, today I just hope to recover the capital invested 7 years ago!
However if we suddenly get a news from the FDA, I'd be happy to see the stock over $ 1 per share.
-----------------------------------------------------------
Anyway, I would appreciate your comment related to:
- Lack of money
- Trials stopped for a long time
- Absence of management
- Bankruptcy that everyone waited and never arrived.
.
News !
The web designer is working tonight on new Avax website...
I think you have nose for business like a hound dog ... or you have sensitive crystal ball …
.
How can you be so optimistic?
No updates since some years, trials has been stopped since long time, white web site, without money and without lenders ...
Are you a pumper or do you have confidential information?
.
I hope this nightmare that lasts since long years soon ends for shareholders.
Especially for sick people who seek in DCvax a life expectancy!
--------------------------------------------------------------
Waiting for Linda Power (nicknamed Lady Godot):
"Waiting for Godot" is one of Samuel Beckett's most famous theatrical works. A drama associated with the so-called absurd theater and built around the expectation state ...
Vladimir and Estragon are waiting for a certain "Lord Godot" on a desolate country road. There is nothing on the scene, only a tree behind the two characters that regulates the temporal conception through the fall of the leaves that indicates the passing of days. But Godot never appears on the scene, and nothing is known about his account. He is only sending a boy by two vagabonds, who will tell the two characters that Godot will "not come today, but will come tomorrow."...
.
AVAX website is disappeared ...
http://www.avax-tech.com/
Whois Search Results:
https://reports.internic.net/cgi/whois?whois_nic=avax-tech.com&type=domain
.
Does anyone knows how long time we need to comeback on Nasdaq, if the stock will go over $1 per share?
Maybe 1 month...?
Thanks!
.
Sent, excuse me, maybe you missed reading the phrase indicated before the circle highlighted in red ... It is not $ 10 for every click ...
Average monthly searches: 100 - 1 k = $ 10
The problem is to understand why the FDA pays!
Find out why the UCLA Brain Tumor Program continues to shine as a beacon of hope #DCVAX http://b.autovist.com/e3085774
04:06 - 3 feb 2017
See below on Twitter:
Find out why the UCLA Brain Tumor Program continues to shine as a beacon of hope #DCVAX https://t.co/cC1xv0ouVb
— CancerSurvivalnvest (@cancersurvest) February 3, 2017
Personalized Cancer Vaccines and Neoantigen Targeted Therapies
THURSDAY, August 31
11:45 Dendritic Cell Immunotherapy for Solid Tumors
Marnix Bosch, Ph.D., CTO, Northwest Biotherapeutics
The capacity of dendritic cells (DCs) to initiate adaptive immune responses can be harnessed for cancer immunotherapy purposes. Northwest Biotherapeutics has developed two product lines in which autologous DCs are utilized to present tumor antigens to the immune system, with the goal to affect tumor growth and extend patients’ lives in the absence of significant toxicity. These products are being tested in both late stage and early stage clinical trials in which both the efficacy of the products as well as the scientific underpinnings of the technology are being further evaluated.
FRIDAY, SEPTEMBER 1
8:30 KEYNOTE PRESENTATION: Broad Coverage HLA-DR Subdominant Neoepitope-Based Cancer Vaccines
Keith Knutson, Ph.D., Director, Cancer Vaccine & Immune Therapies Program, Mayo Clinic
Vaccines that elicit helper T cells are effective in preventing tumor growth. Dominant class II epitopes drive tolerance through the generation of Tregs. There is a T cell repertoire to subdominant epitopes, the latter of which are presented during aberrant protein expression such as in tumors. We have developed pathways for identifying subdominant class II epitopes that bind promiscuously to HLA-DR molecules, establishing broad coverage helper T cell-inducing cancer vaccines.
http://www.immuno-oncologysummit.com/Personalized-Cancer-Vaccines/
.-
Someone might be interested to follow posts on Twitter:
https://twitter.com/SenJohnMcCain
https://twitter.com/MeghanMcCain Daughter of Senator John McCain
https://twitter.com/cindymccain Wife of Senator John McCain
.-
Everybody waiting for update about trials, I believe and feel that update will never be released.
Linda Power is too smart to give news as food to the sharks… (Basher, Fund, Pharmaceutical Lobby).
I believe that we will see soon a great Press Release, probably the evening before opening Stock Market…
My forecast as following:
BETHESDA, Md., September 23, 2017 – Northwest Biotherapeutics (OTCQB: NWBO) (“NW Bio” or the “Company”), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that has been APPROVED by the FDA the Trial DCVax®-L for Glioblastoma multiforme (“GBM”) brain cancer…
.-
From YAHOO board:
Michael 9 hours ago
In Q4 NWBO is going to explode to the positive. Quite awhile back, I did a Seeking Alpha article that was balanced in its assessment of the equity. At that time, I suggested that when the study results were released the primary endpoint would be attained in a statistically significant way. I also believed that secondary endpoints including OS would report positive. I did, however, caution longs that the FDA would have serious questions about the long evolution of the trial, the impact of the crossover effect on the control arm, and so on.
I am now prepared to tell you that the delay in releasing the results of this trial is likely because the company wants the data to be analyzed thoroughly and presented in a manner that will withstand criticism from the one person in biotech ideation that is going to be blindsided and brutally beaten by this disclosure when it comes.
The long wait will soon be over and longs will go from dejected and demoralized to confident as kings. Northwest BioTherapeutics will be the biggest story in biotech. Bigger than Amarin was. Bigger than MannKind. Bigger than Sarepta.
Look lively and always be well...
---------------------------------------------
Replies (2)
Dennis 7 hours ago
I am not sure of your timing but I too have reviewed the primary and the possible OS data and without a doubt this is going to wake many people up from a very deep sleep.
---------------------------------------------
Boris 7 hours ago
Why not in Q3 ? data was meant to be locked in first half of july lol
a story just as large as celator or aquinox is enough for me :)
.-
What I think of investors... Well, I can say that I invested everything on NWBO, until my last dollar and I bought to $0.45 per share...
I also made debts to invest on NWBO...
I hope there will not be a Reverse Split now, if it will be necessary an RS, I hope that Linda Power is so clever and sensible to postpone after the price per share will exceed $12, otherwise thousands of investors will be robbed because they can no longer recover the invested capital!
.-
I have identified myself in the office of CEO Linda Power:
a) I state that I would already know since many months or years the results of the trial DCvax-L and DCvax-Direct.
b) I as CEO, I would have commissioned a sample study of trials on 20-30 patients, so even if the official results are blinded, I would know already with good approximation the success or failure of the vaccines.
Therefore I would behave as Linda Power exclusively in two opposite cases:
The Fable for children of the waiting of the 2 patients still alive, it is valid for both point 1 and Point 2.
1) Official knowledge of the failure of DCvax trials and last attempt to deepen the studies before issuing a Public Release.
2) Official knowledge of the success of DCvax trials and frequent encounters with the FDA in the utmost discretion, pending imminent Accelerated Approval.
I think Linda Power has done what is reported in point b and that she is waiting for AA as indicated in point 2.
Best wishes to all patients and long-term shareholders...
.
July 17, 2015 NWBO's best stock price!
2nd Anniversary of $12 ...
I hope to find good news by Monday 17 to return quickly on value NWBO deserves and on NASDAQ Market ...
.
Conference programme:
27th September to 28th September 2017, London, United Kingdom
11:00 - (DCVax®: Novel personalised immune therapies for solid tumours)
Linda Powers, CEO, Northwest Biotherapeutics Inc
• DCVax® is a fully personalised precision medicine, tailored to the individual patient and their tumour
• DCVax® is designed to mobilise many active agents of the immune system to hit many targets on the cancer, unlike conventional cancer drugs and some other immune therapies, which generally use a single active agent to hit a single target on the cancer
• A full course of DCVax® doses can be manufactured in a single batch within about a week, and can be stored frozen until needed (including for years)
https://www.smi-online.co.uk/pharmaceuticals/uk/cancer-vaccines?utm_medium=www.cancervaccinesevent.com&utm_source=P-221&utm_campaign=ihub#tab_programme
.
I would like to thank you for your commitment to spreading the efficacy of the DCvax-L vaccine, via Twitter, especially to Dr. Gottlieb.
What you say is right: it is important to talk of patients who are waiting for effective care, and if necessary to talk ours financial investments.
However, I would like to point out that it would also be important for Dr. Gottlieb to become aware of the urgency NWBO needs...
The continuous attacks of naked shorters, fake information, etc., have knocked NWBO, so it risks killing the research and the success of a new cure.
Therefore, on my part and millions of patients waiting for care, I would like to suggest you to inform Dr. Gottlieb of the bankruptcy risk to which NWBO is subjected.
Thank you in advance!
.
Fasten belts, take off should take place within two weeks (June 17) ...
.
... Rather than conducting a lengthy and expensive series of separate trials to discover which patients might benefit most from a drug, a single adaptive trial could come to the same conclusion after only one study that was allowed to “flex” along the way. ...
... Yes, he is a doctor. He’s also been a patient.
Gottlieb is a cancer survivor, having been successfully treated for Hodgkin’s lymphoma.
That experience prompted Gottlieb to become a cancer policy advisor for the National Coalition for Cancer Survivorship. The coalition, in turn, strongly endorsed his nomination to head the FDA.
In a statement issued when Trump nominated him in mid-March, the coalition said that Gottlieb “understands the human toll cancer takes on individuals and families, during both treatment and long-term survivorship. He is open to a wide range of perspectives, including those of the patients whose lives depend on a strong FDA.” ...
http://www.latimes.com/science/sciencenow/la-sci-sn-scott-gottlieb-fda-20170510-htmlstory.html
.